BPC-157 vs Metformin
Both are used for gut health. Here's how they compare on human evidence, mechanism, safety and availability — in plain English.
| BPC-157 | Metformin | |
|---|---|---|
| Human evidence | ★★★☆☆ | ★★★★★ |
| Legal status | Not Approved | Off-Label, FDA Approved |
| How it works | A 15-amino-acid fragment of a gastric protein. Two characterised pathways: (1) upregulates VEGFR2 (KDR) → PI3K/Akt → eNOS (NOS3), driving angiogenesis (new blood vessels to injured tissue); (2) a Src–Caveolin-1–eNOS route. It also… | Inhibits mitochondrial Complex I, raising the AMP:ATP ratio → activates AMPK. How the AMPK "burn, don't hoard" switch works → the AMPK pathway. On top of that it lowers hepatic gluconeogenesis, improves insulin sensitivity and reshapes the… |
| In plain English | It tells injured tissue to grow a fresh blood supply (via the VEGFR2 switch), and blood flow is what healing runs on — so tendons, ligaments, gut lining and muscle appear to mend faster. The catch: almost all the evidence is in rats. Human… | Metformin trips the same low-fuel switch (AMPK) that exercise does. Diabetics on it have outlived non-diabetics in some data. The catch for athletes: because it partly duplicates the exercise signal, it can blunt muscle and fitness gains… |
| Bottom line | The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision. | Best for the sedentary/metabolically-at-risk; may cost gains if you train hard. |
| Availability | Not widely approved | Prescription only |
Which is better for gut health?
Metformin has the stronger human-evidence rating (★★★★★ vs ★★★☆☆), but the right choice still depends on your goal, tolerance and budget.
Common questions
Is BPC-157 or Metformin better for gut health?
Metformin has the stronger human-evidence rating (★★★★★ vs ★★★☆☆), but the right choice still depends on your goal, tolerance and budget.
What's the difference between BPC-157 and Metformin?
BPC-157: The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision. — Metformin: Best for the sedentary/metabolically-at-risk; may cost gains if you train hard.